Start treating patients at Stage B2 . Recommended by the ACVIM (Specialty of Cardiology) for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD) (2019 ACVIM Consensus Statement 1 ).
-CA1
BASED ON A STUDY, DOGS TREATED WITH VETMEDIN®-CA1 (PIMOBENDAN) DEMONSTRATED AN AVERAGE OF 15 MONTHS OF PROLONGED, SYMPTOM-FREE LIFE COMPARED TO DOGS TREATED WITH A PLACEBO. 2
IMPORTANT SAFETY INFORMATION: Adverse reactions not related to disease progression in dogs receiving VETMEDIN ® -CA1 (pimobendan) included diarrhea, vomiting, pain, lameness, arthritis, urinary tract infection, and seizure. The safe use of VETMEDIN-CA1 has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. It is a violation of Federal law to use this product other than as directed in the labeling . For more information, refer to the package insert.
1 Keene, BW, Atkins, CE, Bonagura, JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med . 2019; 33: 1127–1140. 2 VETMEDIN ® -CA1 (pimobendan) Chewable Tablets [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2022.
VETMEDIN ® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0391-2022
Made with FlippingBook Online newsletter maker